Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31454335 | 0.89 | MAPT (0.56) | GAAMAPTALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL422548 | 0.89 | MAPT (0.56) | GAAMAPTALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL25252974 | 0.87 | KDM4E (0.59) | GAAMAPTALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL23981491 | 0.86 | KDM4E (0.62) | GAAMAPTALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL4100817 | 0.85 | GAA (0.53) | GAAMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL18984039 | 0.84 | GAA (0.53) | GAAMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL20097526 | 0.84 | PRKDC (0.55) | GAAMAPTALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL25262426 | 0.83 | ALOX15 (0.50) | GAAMAPTALOX15ALDH1A1MAPK1 | |
| SCHEMBL21549442 | 0.83 | SMN1; SMN2 (0.50) | GAAMAPTALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL23059699 | 0.82 | MAPT (0.56) | GAAMAPTALOX15SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| CN-106456602-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2020-11-24 | — | — | CN | disclosed |
| EP-3122353-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200140447-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2020-05-07 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
| EP-3122353-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148854-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | GAA 1755/4885MAPT 2157/4885ALOX15 1439/4885 |
| US-20200140447-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | GAA 4009/4885MAPT 3014/4885ALOX15 2271/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | GAA 305/4885MAPT 3417/4885ALOX15 2880/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | GAA 1755/4885MAPT 2157/4885ALOX15 1439/4885 |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | GAA 4009/4885MAPT 3014/4885ALOX15 2271/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | GAA 1755/4885MAPT 2157/4885ALOX15 1439/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | GAA 4009/4885MAPT 3014/4885ALOX15 2271/4885 |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | GAA 4009/4885MAPT 3014/4885ALOX15 2271/4885 |
| US-11208415-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | GAA 4009/4885MAPT 3014/4885ALOX15 2271/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | GAA 305/4885MAPT 3417/4885ALOX15 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.